JUVENESCENCE Appoints Dr Richard Marshall CBE as CEO
Juvenescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023. Dr Marshall succeeds co-founder Dr Gregory Bailey, who will remain on the company’s board as Executive Chairman.
Dr Marshall brings over twenty years of business leadership to the company, with fifteen years at GSK culminating in his position as Vice President, Head of the Fibrosis & Lung Injury Discovery Performance Unit (DPU). Most recently, Dr Marshall was Senior Vice President, Global Development Head, Respiratory & Immunology of AstraZeneca. Dr Marshall was awarded a CBE in the 2021 Queen’s Honours List for his contribution to UK science and COVID-19.
“I am delighted that Dr Richard Marshall CBE, the former Senior Vice-President, Global Head of Development, Respiratory & Immunology at AstraZeneca, has agreed to lead Juvenescence as CEO. Throughout his career, Richard has been the architect of numerous transformative R&D strategies to drive innovation and deliver rapid growth, with a track record of collegial success, building high performing teams and developing novel therapies,” outgoing CEO Dr Gregory Bailey said. “Richard is a results-oriented leader who believes that in a post-COVID-19 world facing the impending crisis of an inverted demographic pyramid coupled with undercapitalized pension funds and ever-increasing healthcare costs, proactive, decentralized solutions are desperately needed. Juvenescence is a critical player in the mega-trends now driving towards the healthier lifestyles and digital health strategies needed to confront these issues. I am confident that with this appointment, we have a world class team with the experience and skillset to position Juvenescence as one of the premier biotech and pharmaceutical companies focused on modifying aging through prevention.”
Dr Richard Marshall CBE said, “I am thrilled to be joining Juvenescence at such a pivotal point in the company’s history. They are at a real inflection point, with an incredible opportunity to build on Juvenescence’s trusted brand and the Founders’ 30-year history of developing drugs to bring innovative approaches to modify and prevent the impact of aging to the market. With its broad portfolio and depth of experience, Juvenescence is building a unique ecosystem of key partnerships and acquiring the critical capabilities needed for success in this rapidly evolving field. I look forward to working with the team, our partners, and shareholders to capitalize on this incredible opportunity.”
About Juvenescence
Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan. It was founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan. The Juvenescence team consists of highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in pharmaceutical drug development, synthetic biology, and tissue and cellular engineering.
Juvenescence has a broad portfolio of products in development and is driving innovation, with a focus on discovering and developing these therapies to modify the aging process, through prevention and by regenerating damage, to support healthy aging and increase health span. The company is committed to inspiring and equipping the world to, not just reimagine what it means to age, but to help people Reimagine A Lifetime. For more information see: www.JuvLabs.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005022/en/
Contact information
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Declares Dividend for Second Quarter 20241.5.2024 22:15:00 CEST | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 10, 2024 to shareholders of record as of June 21, 2024. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20240501801418/en/Contact information Media Relations: Paulina Heinkel 332.877.5339 Media.request@iff.com Investor Rela
Qualcomm Earnings Release Available on Company’s Investor Relations Website1.5.2024 22:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced the Company’s financial results for its second quarter of fiscal 2024 through an earnings release that is available on the Qualcomm Investor Relations website at http://investor.qualcomm.com/results.cfm. The earnings release will also be furnished to the Securities and Exchange Commission (SEC) on a Form 8-K and will be available on the SEC website at http://www.sec.gov. As previously announced, Qualcomm will host a conference call to discuss its fiscal second quarter results which will be broadcast live on May 1, 2024, beginning at 1:45 p.m. Pacific Time (PT) at http://investor.qualcomm.com/events.cfm. An audio replay will be available at http://investor.qualcomm.com/events.cfm and via telephone following the live call for 30 days thereafter. To listen to the replay via telephone, U.S. callers may dial (877) 660-6853 and international callers may dial (201) 612-7415. Callers should use reservation number 13745532. About Qualcomm Qua
Oceansix Announces Full-Year 2023 Financial Results1.5.2024 20:24:00 CEST | Press release
Oceansix Future Paths Ltd. (“Oceansix” or the “Company”), a leader in sustainable technology and manufacturing, today announced its financial results for the year ended December 31, 2023. The Company is publicly traded on the TSX Venture Exchange (TSXV: OSIX), the New York OTCQB (AKMYF), and the Frankfurt Stock Exchange (WKN: A3EFB0). Annual Financial Highlights: Sales Growth: Significant growth of sales in our key subsidiary, Flome, showcasing strong market performance and product demand. Bottom Line Improvement: Adjusted bottom line shows considerable progress, factoring in recoverable impaired amounts and other incomes. E-commerce Focus: The e-commerce project remains central to our strategy, with promising updates expected soon. Shareholder Support: Strong commitment from existing shareholders to support and expand their stakes in the company, underlining confidence in our growth trajectory. Financial Statements and Detailed Analysis The full consolidated financial statements and t
LambdaTest Enhances Security and Performance with SOCKS5 Proxy and HTTP/2 Support1.5.2024 18:00:00 CEST | Press release
LambdaTest, a leading cloud-based unified testing platform, announced enhanced functionalities within its LambdaTest Tunnel feature. These advancements include comprehensive support for SOCKS5 proxies and built-in HTTP/2 protocol handling, empowering developers and QA professionals with a more secure, performant, and future-proof testing environment. LambdaTest Tunnel now seamlessly integrates with SOCKS5 proxies, offering an additional layer of security for data transmission during testing. This is particularly valuable for users working within complex network environments or those requiring unrestricted access to internal web applications. Additionally, the tunnel feature simplifies testing modern web applications by offering automatic support for HTTP/2, the latest web protocol. This eliminates the need for manual configuration and ensures accurate performance testing that reflects real-world browser-server interactions. “The addition of SOCKS5 proxy support and automatic HTTP/2 han
Rocket Software Closes $2.275B Acquisition of OpenText’s Application Modernization and Connectivity Business1.5.2024 16:05:00 CEST | Press release
Rocket Software, Inc. (“Rocket Software”), a global technology leader in modernization software, has expanded upon its position as a partner of choice empowering the world's leading businesses on their modernization journeys. Closing the acquisition of the Application Modernization and Connectivity (AMC) business of OpenText, formerly part of Micro Focus, Rocket Software now offers customers modernization software solutions spanning the mainframe to the cloud. With a total purchase price of $2.275 billion, before taxes, fees and other adjustments, the deal increases the company’s revenue by over 60% and expands its customer base to more than 12,500 companies and network to more than 750 partners worldwide. In addition, the company welcomes more than 770 new software engineers, go-to-market professionals and other supporting team members and is hiring hundreds of additional Rocketeers to complement its existing team. “Rocket Software’s customers are global market leaders that are consta